Norepinephrine Reuptake Inhibitors And Risk Of Antihypertensive Treatment Intensification And Major Adverse Cardiovascular Events In Patients With Stable Hypertension And Depression
Study Objective: To compare the risk of antihypertensive treatment intensification (TI) and major adverse cardiovascular events (MACE) with the initiation of serotonin norepinephrine reuptake inhibitors compared to selective serotonin reuptake inhibitors (SSRIs) in patients with stable hypertension and depression. Design: Retrospective cohort study. Data Source: IBM MarketScan® commercial claims database and Medicare Supplemental claims database from 2007 to 2019. Patients: Patients aged 18 years or older with stable treated hypertension and depression who newly initiate either serotonin norepinephrine reuptake inhibitors or SSRIs. Intervention: Serotonin norepinephrine reuptake inhibitors versus SSRIs. Measurements and Main Results: The primary outcomes were: (1) TI (first occurrence of antihypertensive regimen augmentation or dose escalation); (2) MACE (first occurrence of stroke or acute myocardial infarction). Baseline risk between the two groups was balanced via 1:1 propensity score (PS) matching. A Cox proportional hazard regression model was used to estimate adjusted hazard ratio (aHR) and 95% confidence intervals (95% CI). After 1:1 PS matching, we included 19,160 patients in the study cohort (mean age: 52 years, 62% females) of which 9580 initiated serotonin norepinephrine reuptake inhibitors and 9580 initiated SSRIs. Patients who initiated serotonin norepinephrine reuptake inhibitors had 15 MACE events (incidence rate per 1000 person-years [IR], 3.9) and 1675 TI events (IR, 540.2), compared with 17 MACE events (IR, 4.0) and 1774 TI events (IR, 518.5) in the SSRI group. The risk of TI (aHR: 1.01, [95% CI: 0.94, 1.08]) and MACE (aHR: 0.98, [95% CI: 0.49, 1.96]) did not differ among patients initiated serotonin norepinephrine reuptake inhibitors versus SSRIs. Conclusions: Among patients with stable hypertension and depression, initiation of serotonin norepinephrine reuptake inhibitors had a similar risk of antihypertensive TI and MACE compared to initiation of SSRIs. Future study with a larger sample size is needed to confirm our findings.
Desai, Raj; Park, Haesuk; Brown, Joshua D.; Mohandas, Rajesh; and Smith, Steven M., "Norepinephrine Reuptake Inhibitors And Risk Of Antihypertensive Treatment Intensification And Major Adverse Cardiovascular Events In Patients With Stable Hypertension And Depression" (2022). School of Medicine Faculty Publications. 883.